FilingReader Intelligence

Huahai Pharmaceutical receives approval for tolvaptan tablets

June 9, 2025 at 09:54 PM UTCBy FilingReader AI

Zhejiang Huahai Pharmaceutical (SSE:600521) announced that it has received a drug registration certificate from the National Medical Products Administration for its Tolvaptan Tablets. The drug, categorized as a Class 4 chemical drug, is indicated for the treatment of hyponatremia and fluid retention caused by heart failure. Developed originally by Otsuka Pharmaceutical Co., Ltd., Tolvaptan Tablets had an estimated market value of CNY 497 million in China during 2024, according to data from Menet. Huahai Pharmaceutical has invested CNY 9.51 million in the research and development of Tolvaptan Tablets. The company cautioned that the production and sales of the drug remain subject to policy and market uncertainties, and advised investors to exercise caution.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600521Shanghai Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →